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Saving myelin from microglia
The blood clotting protein fibrinogen can inadvertently promote 
multiple sclerosis (MS) when it leaks from the blood into the 
brain. According to Adams et al. (page 571), it does so by 
activating microglia and sending these cells into phagocytic 
overdrive. Interrupting this interaction may yield a treatment 
for MS that doesn’t interfere with blood clotting.
The neurological dysfunction seen in MS is caused by the 
destruction of myelin sheaths around axons. This destruction 
is thought to be driven by T helper (Th)-1 cells, and most of 
the current treatment protocols are focused on inhibiting their 
activation and entry into the CNS. But responses to anti–T cell 
therapy are variable, and inflammatory demyelination can 
sometimes occur in the absence of T cells.
One feature that all MS lesions have in common is a disruption 
in the blood–brain barrier and the leakage of fibrinogen into the 
brain through the damaged endothelia. This results in the formation 
of fibrin deposits, which are detected even before demyelination. 
These deposits also overlap with regions where resting microglia 
have differentiated into phagocytic cells that damage myelin, 
raising the possibility that clotting proteins activate microglia.
Akassoglou and colleagues had previously shown that 
fibrinogen promotes disease in mouse models of MS. The team 
now shows that fibrinogen binds to a macrophage-activating 
receptor called Mac-1 that is expressed by local microglial cells.
Mice expressing a mutant form of fibrinogen that fails to bind 
Mac-1 had fewer inflammatory lesions and less severe disease. 
Blocking the fibrinogen–Mac-1 interaction with an antagonist peptide 
prevented relapses and further myelin damage in diseased mice and 
allowed these animals to survive with improved motor function.
Fibrinogen is an attractive target for MS therapy as its 
appearance in the brain is an early sign of neurodegeneration. 
Current methods to target fibrinogen involve the use of 
anticoagulants, but their long-term use increases the risk of 
hemorrhage. The region of fibrinogen that promotes clotting is, 
however, distinct from its Mac-1–activating site. Specifically 
targeting the latter interaction might therefore be a safer option 
in MS therapy, although it is not yet clear whether T cell–
dependent pathways would also need to be blocked. 
Switching defects
Switching from one antibody isotype to 
another is a risky business that involves 
altering and cleaving DNA. B cell lym-
phomas that are stuck in the riskiest stage 
suffer repeated mutations and insertions 
that may further drive oncogenesis, ac-
cording to Lenz et al. on page 633.
Mature B cells switch from producing 
IgM to other antibody isotypes during 
their response to antigen. This process, 
known as class switch recombination 
(CSR), is initiated by an enzyme called 
activation-induced cytidine deaminase 
(AID). Modification of DNA bases by AID 
within a so-called switch region leads to 
DNA cleavage. An intervening sequence 
is looped out, and two cleaved switch 
regions are ligated together to create a new 
gene encoding a new antibody isotype.
The group had previously found 
that the activated B cell–like (ABC) 
lymphomas had high expression of AID 
compared with certain other lymphoma 
subtypes. They now find that almost 
two-thirds of the ABC lymphoma cells 
tested have abnormal CSR events and 
almost half have internal deletions in 
a switch region. The switch regions 
contained as many as 19 independent 
deletions interspersed with mutations at 
AID hot spots. The changes could be 
organized into lineage models, suggesting 
an ongoing process of aberrant processing.
AID expression is normally a tran-
sient phenomenon that occurs as B cells 
mature. ABC lymphomas, however, are 
stuck at an intermediate phase of B cell 
maturation. One consequence is sus-
tained high levels of AID expression. 
This by itself does not appear to be suffi-
cient to explain the phenotype—another 
lymphoma subtype expresses almost as 
much AID but suffers fewer problems 
with CSR. The AID overexpression in 
ABC lymphomas may be combined with 
a defect (as yet hypothetical) in proteins 
that complete CSR. The frustrated machi-
nery would turn on its own target sites, 
leading to deletions and mutations rather 
than a clean class switch.
In one lymphoma, DNA fragments 
from other chromosomes were inserted 
into the deletion sites, highlighting the 
danger inherent in aberrant class switch 
recombination. Translocations involving 
cancer-causing genes were also observed, 
suggesting that defective switching might 
sometimes further drive oncogenesis in 
these B cell lymphomas. 
Activated B cell–like (ABC) lymphomas 
have a higher rate of intraswitch deletions 
compared with other lymphomas.
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Heavy metal for a troubled heart
Including more copper in your everyday diet could be good for your 
heart, according to a study on page 657. Jiang et al. now find that dietary 
supplementation of copper offsets the effects of stress on an overworked 
heart by preventing its enlargement.
Copper-carrying proteins disarm oxygen radicals and power electron 
transport. Humans with copper deficiency have increased cholesterol levels, 
clot formation, oxidative tissue damage, and heart disease. Cardiac tissue 
biopsies of heart attack victims show a great reduction in copper levels.
In mice with stress-induced heart disease, the team now shows, 
increased heart size and decreased heart function can both be restored 
to normal levels by a small increase in the daily intake of copper, even 
when the stress stimulus is maintained. But without the copper supple-
ment, stressed mice suffer heart failure after two months.
The authors show that mice receiving dietary copper supplements 
have increased activity of a transcription factor called HIF-1α, leading to 
increased production of the vascular endothelial growth factor (VEGF) 
protein, which promotes angiogenesis. Blocking VEGF activity inhibits 
the ability of copper to reverse heart enlargement and dysfunction. It is 
not clear, however, how angiogenesis helps decrease muscle mass or how 
copper gets pushed out of the heart during stress.
The human equivalent of the beneficial dose of copper used in this 
study is  3.0 mg/day. The current recommended daily intake for 
humans, however, is only 0.9 mg/day. Increasing copper intake may be 
a cheap way to reduce mortality associated with heart disease. 
Re-redefining 
Foxp3 function
Liston et al. (page 475) report that a 
transcription factor that protects mice against 
autoimmunity is required for regulatory 
T cell (T reg) function only, and not for thymic 
epithelial cell function, as previously reported.
Mutations in the Foxp3 gene have been 
identified as the basis of autoimmune syndromes 
in both mice and men. This was thought 
to be due to a failure in the development 
of immune-suppressing T reg cells, which has 
been shown to require Foxp3.
However, a recent study indicated that 
Foxp3-lacking bone marrow cells do not cause 
autoimmunity when transferred into mice that 
lack T cells but express Foxp3 in their thymic 
stroma (JEM 202:1141). This suggested that 
Foxp3 also functioned in non–T cells, and that 
the autoimmunity suffered by Foxp3-deficient 
animals might be due not to defective T regs but 
to a defective thymic epithelium.
To Liston et al., a function for Foxp3 outside 
of T regs sounded suspicious, as Foxp3 had 
previously been extensively characterized as being 
specific to T regs. They have now specifically 
deleted Foxp3 in T cells. This targeted deletion 
caused the same full-blown autoimmunity as 
seen in Foxp3-negative mice. The deletion of 
Foxp3 in the non–T cell populations of the 
thymus, however, did not cause disease.
The authors also show that, in normal mice, 
Foxp3 is not expressed in thymic epithelia but 
is limited to T reg cells alone. Although these 
results redefine Foxp3 expression, the reason 
for the disparity between the two papers 
remains unclear. 
Translated to death
An effective alarm leads to an effective 
response. On page 525, Tellam et al. 
show that increased translation of a 
viral protein results in a more effective 
display of epitopes to T cells and thus 
a better immune response.
Most viral epitopes are derived not 
from long-lived stable proteins but from 
defectively translated and rapidly 
degraded intermediates. More translation 
should lead to more intermediates and 
thus more epitope presentation. However, this link has not been convincingly 
shown with identical proteins that have different translation efficiencies.
Tellam and colleagues compared cells translating either EBNA1 from 
Epstein-Barr virus (EBV), or a mutant version of EBNA1 that lacked EBNA1’s 
self-inhibiting sequence and was therefore translated more rapidly.
Cells expressing the normal EBNA1 generated very few epitopes and failed 
to activate T cells. In contrast, cells expressing the mutant EBNA1 produced 
a large number of epitopes, possibly due to the production of more defective 
products, and primed a strong T cell response.
EBV evades the immune response by minimizing EBNA1 translation and 
thus presentation; EBNA1 also inhibits its own degradation so that normal 
levels of protein are maintained. In EBV-associated cancers, increasing 
EBNA1 translation rates by targeting EBNA1’s self-inhibiting sequence may 
lead to increased epitope presentation and thus improve the efficacy of 
cancer therapies using anti-EBV T cells. 
Foxp3 deletion in T cells (CD4-Cre) but not thymic 
epithelial cells (Foxn1-Cre) causes an autoimmune 
wasting disease.
Highly translated EBNA∆GA 
induces a stronger T cell response.